RxDoctor Payments Data

Shauna Johnson, APRN

Nurse Practitioner · Savannah, GANPI 1366933558

Payments from drug & device makers

$4,152in general payments, 2019–2025

Across 214 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$728
  • Teva Pharmaceuticals USA, Inc.$576
  • AbbVie$564
  • Indivior Inc.$410
  • Johnson & Johnson$375
  • Neurocrine Biosciences, Inc.$357
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,11199%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,152 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$6,829
Medicare patients
26
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate76$182,391
Abilify MaintenaAripiprazole36$102,778
VraylarCariprazine Hcl30$44,045
TrintellixVortioxetine Hydrobromide34$16,755
Aripiprazole43$5,428
Asenapine Maleate24$4,591
Clozapine23$3,792
Lurasidone Hcl31$2,626
Quetiapine Fumarate122$2,006
Ziprasidone Hcl50$1,658
Divalproex Sodium55$1,606
Risperidone108$1,437
Benztropine Mesylate83$1,204
Olanzapine87$1,143
Haloperidol43$952

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$375$182,39176 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$728$102,77836 claims
AbbVieVraylar$564$44,04530 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$16,75534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →